Qihan Biotech, established in 2017 by two trailblazers in genome editing technology, is a leading brand with expertise in multiplexable genome editing and immune shielding. With a focus on both human stem cells and animal germline cells, we are dedicated to developing cutting-edge immune-privileged cell and organ therapies. Our wide range of products and services includes organs such as the kidney, intestine, heart, lung, liver, and skin, as well as islet cells, cardiomyocytes, neurons, and immune cells.

At Qihan Biotech, our vision is to make cell and organ therapies universally accessible to patients worldwide. To achieve this, we utilize multiplexable genome editing techniques combined with extensive knowledge in transplantation immunology. Our mission is to create immunologically privileged allogenic cells and xenogeneic organs to treat cancer, organ failure, and other significant medical conditions.

With a strong emphasis on innovation, commitment, integrity, and ownership, Qihan Biotech is led by a board of experienced individuals with successful biotech startup backgrounds. Additionally, we have esteemed scientific advisors, including renowned figures like George Church and James Markmann, who bring diverse research and clinical expertise to our organization. Contact us today to learn more about how Qihan Biotech is revolutionizing the field of genome editing and immune-privileged therapies